BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 25022066)

  • 1. [The current status of genetic testing for leukemia].
    Satoh Y; Masuda A; Yokota H; Yatomi Y
    Rinsho Byori; 2014 Apr; 62(4):369-77. PubMed ID: 25022066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The current status of leukemia genetic testing and the trial of its standardization].
    Satoh Y; Yokota H; Kageyama Y; Ono Y; Yatomi Y
    Rinsho Byori; 2008 May; 56(5):395-401. PubMed ID: 18546889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chromosome analysis of and genetic testing for myeloid leukemia].
    Yokota H; Yatomi Y
    Nihon Rinsho; 2009 Oct; 67(10):1911-5. PubMed ID: 19860189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular diagnosis of hematopoietic and lymphoid neoplasms.
    Jevremovic D; Viswanatha DS
    Hematol Oncol Clin North Am; 2009 Aug; 23(4):903-33. PubMed ID: 19577174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.
    van der Velden VH; Hochhaus A; Cazzaniga G; Szczepanski T; Gabert J; van Dongen JJ
    Leukemia; 2003 Jun; 17(6):1013-34. PubMed ID: 12764363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal residual disease testing in hematologic malignancies and solid cancer.
    Ben Lassoued A; Nivaggioni V; Gabert J
    Expert Rev Mol Diagn; 2014 Jul; 14(6):699-712. PubMed ID: 24938122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.
    Gabert J; Beillard E; van der Velden VH; Bi W; Grimwade D; Pallisgaard N; Barbany G; Cazzaniga G; Cayuela JM; Cavé H; Pane F; Aerts JL; De Micheli D; Thirion X; Pradel V; González M; Viehmann S; Malec M; Saglio G; van Dongen JJ
    Leukemia; 2003 Dec; 17(12):2318-57. PubMed ID: 14562125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of minimal residual disease in acute leukemia patients.
    van Dongen JJ; Szczepański T; de Bruijn MA; van den Beemd MW; de Bruin-Versteeg S; Wijkhuijs JM; Tibbe GJ; van Gastel-Mol EJ; Groeneveld K; Hooijkaas H
    Cytokines Mol Ther; 1996 Jun; 2(2):121-33. PubMed ID: 9384697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Study on the analytical error factors and evaluation of an internal control gene for leukemia gene expression analysis].
    Satoh Y; Yokota H; Takai D; Yatomi Y
    Rinsho Byori; 2012 Aug; 60(8):740-7. PubMed ID: 23198532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [DNA diagnosis in hematological malignancies].
    Nara N
    Rinsho Byori; 2001 Mar; Suppl 115():37-44. PubMed ID: 11391935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCR for monitoring of minimal residual disease in hematologic malignancy.
    Matsuda K; Sugano M; Honda T
    Clin Chim Acta; 2012 Jan; 413(1-2):74-80. PubMed ID: 22057038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The minimal residual disease (MRD) in hematological malignancies].
    Yokota S; Okamoto T
    Gan To Kagaku Ryoho; 2001 Jun; 28(6):762-8. PubMed ID: 11432342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Minimal residual disease in malignant diseases of the blood I. Background and pre-clinical validation].
    Hokland P; Nyvold CG; Stentoft J; Ommen HB; Ebbesen LH; Braendstrup K; Andersen BL; Mikkelsen LS; Ostergaard M
    Ugeskr Laeger; 2009 Jan; 171(4):229-31. PubMed ID: 19174037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of minimal residual disease using allele (mutation) -specific PCR].
    Matsuda K
    Rinsho Byori; 2014 Jun; 62(6):552-9. PubMed ID: 25151774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiplex RT-PCR for the detection of leukemia-associated translocations: validation and application to routine molecular diagnostic practice.
    Salto-Tellez M; Shelat SG; Benoit B; Rennert H; Carroll M; Leonard DG; Nowell P; Bagg A
    J Mol Diagn; 2003 Nov; 5(4):231-6. PubMed ID: 14573782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective application of a multiplex reverse transcription-polymerase chain reaction assay for the detection of balanced translocations in leukaemia: a single-laboratory study of 390 paediatric and adult patients.
    Olesen LH; Clausen N; Dimitrijevic A; Kerndrup G; Kjeldsen E; Hokland P
    Br J Haematol; 2004 Oct; 127(1):59-66. PubMed ID: 15384978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction.
    van Dongen JJ; Breit TM; Adriaansen HJ; Beishuizen A; Hooijkaas H
    Leukemia; 1992; 6 Suppl 1():47-59. PubMed ID: 1548936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Detection of MRD and its clinical application--review].
    Zhu YM; Chen SJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):1131-6. PubMed ID: 16403298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytogenetic aspects of childhood leukemias.
    Lampert F; Harbott J; Borkhardt A
    Klin Padiatr; 2013 May; 225 Suppl 1():S30-3. PubMed ID: 23700053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
    Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
    Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.